Phase 3 Clinical Trials With Primary Completion Dates in March 2020
This is a list of Phase 3 trials with primary completion dates in March 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABSCF | AB Science S.A. | 2020-03-01 | Phase 3 | NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer |
| AMPE | Ampio Pharmaceuticals, Inc. | 2020-03-01 | Phase 3 | NCT03988023 | Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. |
| AXSM | Axsome Therapeutics, Inc. | 2020-03-01 | Phase 3 | NCT04163185 | Initiating Early Control of Migraine Pain and Associated Symptoms |
| AXSM | Axsome Therapeutics, Inc. | 2020-03-01 | Phase 3 | NCT02741791 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder |
| BPMUF | Basilea Pharmaceutica AG | 2020-03-01 | Phase 3 | NCT03439124 | Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia |
| CARA | Cara Therapeutics, Inc. | 2020-03-01 | Phase 3 | NCT03998163 | CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus |
| CARA | Cara Therapeutics, Inc. | 2020-03-01 | Phase 3 | NCT03636269 | CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 2020-03-01 | Phase 3 | NCT03398837 | Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis |
| CYAD | Celyad SA | 2020-03-01 | Phase 3 | NCT02317458 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL |
| HESG | Health Sciences Group, Inc. | 2020-03-01 | Phase 3 | NCT04249336 | Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH |
| MESO | Mesoblast Limited | 2020-03-01 | Phase 3 | NCT02412735 | Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain |
| MGNX | MacroGenics, Inc. | 2020-03-01 | Phase 3 | NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer |
| NEPH | Nephros, Inc. | 2020-03-01 | Phase 3 | NCT02476279 | Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis |
| NVAX | Novavax, Inc. | 2020-03-01 | Phase 3 | NCT04120194 | Phase 3 Pivotal Trial of NanoFlu⢠in Older Adults |
| OBSV | ObsEva SA | 2020-03-01 | Phase 3 | NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
| ONPH | Oncology Pharma Inc. | 2020-03-01 | Phase 3 | NCT00433589 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes |
| QURE | uniQure N.V. | 2020-03-01 | Phase 3 | NCT03569891 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients |
| RIGL | Rigel Pharmaceuticals, Inc. | 2020-03-01 | Phase 3 | NCT02077192 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| SCYX | SCYNEXIS, Inc. | 2020-03-01 | Phase 3 | NCT03987620 | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis |
| SUPN | Supernus Pharmaceuticals, Inc. | 2020-03-01 | Phase 3 | NCT02691182 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) |
| SYNH | Syneos Health, Inc. | 2020-03-01 | Phase 3 | NCT02810444 | Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID |
| TGTX | TG Therapeutics, Inc. | 2020-03-01 | Phase 3 | NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) |